Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11(3):450–62.
Article
CAS
PubMed
Google Scholar
Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J transplant off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(11):2520–31. doi:10.1111/j.1600-6143.2009.02799.x.
Article
CAS
Google Scholar
Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68–74. doi:10.1097/TP.0b013e3181e065de.
Article
CAS
PubMed
Google Scholar
Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int. 2014;85(2):258–64. doi:10.1038/ki.2013.300.
Article
CAS
PubMed
Google Scholar
Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87(10):1505–13. doi:10.1097/TP.0b013e3181a44206.
Article
CAS
PubMed
Google Scholar
Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol. 2005;17(5):541–5. doi:10.1016/j.coi.2005.07.018.
Article
CAS
PubMed
Google Scholar
Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation. 2008;86(3):377–83. doi:10.1097/TP.0b013e31817c4cb8.
Article
PubMed
Google Scholar
Campos EF, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J transplant off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(10):2316–20. doi:10.1111/j.1600-6143.2006.01503.x.
Article
CAS
Google Scholar
Reinders ME, de Fijter JW, Rabelink TJ. Mesenchymal stromal cells to prevent fibrosis in kidney transplantation. Curr opin organ transplant. 2014;19(1):54–9. doi:10.1097/mot.0000000000000032.
Article
CAS
PubMed
Google Scholar
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22.
Article
CAS
PubMed
Google Scholar
Franquesa M, Hoogduijn MJ, Baan CC. The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. Curr Opin Organ Transplant. 2012;17(4):355–61.
Article
PubMed
Google Scholar
Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722–9.
Article
CAS
PubMed
Google Scholar
Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cell. 2010;28(8):1446–55.
Article
Google Scholar
Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cell Dev. 2009;18(3):475–85.
Article
Google Scholar
Franquesa M, Hoogduijn MJ, Reinders ME, Eggenhofer E, Engela AU, Mensah FK, et al. Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: lessons learned from first clinical trials. Transplantation. 2013;96(3):234–8.
Article
PubMed Central
PubMed
Google Scholar
Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6(2):412–22.
Article
PubMed Central
PubMed
Google Scholar
Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase i study. Stem Cell Transl Med. 2013;2(2):107–11.
Article
CAS
Google Scholar
Reinders ME, Leuning DG, de Fijter JW, Hoogduijn MJ, Rabelink TJ. Mesenchymal stromal cell therapy for cardio renal disorders. Curr Pharm Des. 2014;20(14):2412–29.
Article
CAS
PubMed
Google Scholar
Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012;307(11):1169–77.
Article
CAS
PubMed
Google Scholar
Franquesa M, Herrero E, Torras J, Ripoll E, Flaquer M, Goma M, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev. 2012;21(17):3125–35.
Article
PubMed Central
CAS
PubMed
Google Scholar
Perico N, Casiraghi F, Gotti E, Introna M, Todeschini M, Cavinato RA, et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int. 2013;26(9):867–78.
Article
CAS
PubMed
Google Scholar
Reinders ME, Bank JR, Dreyer GJ, Roelofs H, Heidt S, Roelen DL, et al. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. J Transl Med. 2014;12:331. doi:10.1186/s12967-014-0331-x.
Article
PubMed Central
PubMed
Google Scholar
Beane OS, Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014;9(12):e115963. doi:10.1371/journal.pone.0115963.
Article
PubMed Central
PubMed
Google Scholar
Rando TA. Stem cells, ageing and the quest for immortality. Nature. 2006;441(7097):1080–6.
Article
CAS
PubMed
Google Scholar
Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Age Dev. 2008;129(3):163–73. doi:10.1016/j.mad.2007.12.002.
Article
CAS
Google Scholar
Alagesan S, Griffin MD. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? Curr Opin Organ Transplant. 2014;19(1):65–72. doi:10.1097/mot.0000000000000043.
Article
CAS
PubMed
Google Scholar
Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol. 2013;91(1):40–51.
Article
CAS
PubMed
Google Scholar
Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol JASN. 2009;20(11):2305–13. doi:10.1681/asn.2009020171.
Article
PubMed
Google Scholar
Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol JASN. 1995;6(2):257–63.
CAS
PubMed
Google Scholar
Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol JASN. 2003;14(6):1662–8.
Article
PubMed
Google Scholar
Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the one study. Transplant Res. 2013;2(1):17.
Article
PubMed Central
PubMed
Google Scholar
Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358(4):353–61. doi:10.1056/NEJMoa071074.
Article
PubMed Central
CAS
PubMed
Google Scholar
Reinders ME, Roemeling-van Rhijn M, Khairoun M, Lievers E, de Vries DK, Schaapherder AF, et al. Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy. 2013;15(6):663–72.
Article
CAS
PubMed
Google Scholar
Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, Korevaar SS, Mensah FK, Franquesa M, et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev. 2013;22(21):2825–35. doi:10.1089/scd.2013.0193.
Article
CAS
PubMed
Google Scholar
Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79. doi:10.1001/jama.2012.25321.
Article
CAS
PubMed
Google Scholar
Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013;95(1):161–8.
Article
CAS
PubMed
Google Scholar
Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95(3):410–7.
Article
CAS
PubMed
Google Scholar
Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J transplant off J Am Soc Transplant Am Soc Transplant Surg. 2012;12(5):1157–67. doi:10.1111/j.1600-6143.2012.04013.x.
Article
CAS
Google Scholar
Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation. 2012;94(2):172–7. doi:10.1097/TP.0b013e3182543950.
Article
CAS
PubMed
Google Scholar
Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91(3):342–7. doi:10.1097/TP.0b013e318203fd26.
Article
CAS
PubMed
Google Scholar
Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. New Engl J med. 2013;369(13):1215–26. doi:10.1056/NEJMoa1302506.
Article
CAS
PubMed
Google Scholar
Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95(9):1113–9.
Article
CAS
PubMed
Google Scholar
Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108(6):2114–20. doi:10.1182/blood-2005-11-011650.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I, et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res. 2008;300(3):115–24. doi:10.1007/s00403-007-0827-9.
Article
PubMed
Google Scholar
Seifert M, Stolk M, Polenz D, Volk HD. Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front Immunol. 2012;3:202. doi:10.3389/fimmu.2012.00202.
Article
PubMed Central
PubMed
Google Scholar
Eggenhofer E, Popp FC, Mendicino M, Silber P, Van’t Hof W, Renner P, et al. Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med. 2013;2(8):595–606.
Article
PubMed Central
CAS
PubMed
Google Scholar
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–86. doi:10.1016/s0140-6736(08)60690-x.
Article
PubMed
Google Scholar
Moermans C, Lechanteur C, Baudoux E, Giet O, Henket M, Seidel L, et al. Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation. 2014;98(3):348–53.
Article
PubMed
Google Scholar
Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9(8):1760–72.
Article
CAS
PubMed
Google Scholar
Perico N, Casiraghi F, Gotti E, Introna M, Todeschini M, Cavinato RA, et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant int off J Eur Soc Organ Transplant. 2013;26(9):867–78. doi:10.1111/tri.12132.
Article
CAS
Google Scholar
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. New Engl J med. 2003;349(24):2326–33. doi:10.1056/NEJMoa020009.
Article
CAS
PubMed
Google Scholar
Kalaszczynska I, Ferdyn K. Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. BioMed res int. 2015;2015:430847. doi:10.1155/2015/430847.
Article
PubMed Central
PubMed
Google Scholar
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem cells (Dayton, Ohio). 2004;22(7):1330–7. doi:10.1634/stemcells.2004-0013.
Article
Google Scholar
Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem cell res ther. 2014;5(2):53. doi:10.1186/scrt442.
Article
PubMed Central
PubMed
Google Scholar
Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cell. 2006;24(3):781–92. doi:10.1634/stemcells.2005-0330.
Article
CAS
Google Scholar
Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005;366(9502):2019–25. doi:10.1016/s0140-6736(05)67813-0.
Article
PubMed
Google Scholar